Effect of Carvedilol, Ivabradine or their combination on exercise capacity in patients with Heart Failure (the CARVIVA HF trial)

Maurizio Volterrani, Gennaro Cice, Giuseppe Caminiti, Cristiana Vitale, Salvatore D'Isa, Pasquale Perrone Filardi, Flavio Acquistapace, Giuseppe Marazzi, Massimo Fini, Giuseppe M C Rosano

Research output: Contribution to journalArticle

Abstract

Aim: Patients with heart failure (HF) have reduced exercise capacity. The beneficial effect of beta-blocker on prognosis is not matched by an impact on exercise capacity and quality of life. We performed a randomised open blinded endpoint study to assess the effect of heart rate reduction with carvedilol, ivabradine, and their combination on exercise capacity in HF patients receiving maximal dose of ACE inhibitor. Methods and results: After a run-in phase patients were randomly allocated to 3 groups: carvedilol up to 25 mg bid (n = 38); ivabradine up to 7.5 mg bid (n = 41); and carvedilol/ivabradine up to 12.5/7.5 mg bid (n = 42). The maximal dose of study treatment was more frequently tolerated in patients receiving ivabradine (36/41) than in those receiving carvedilol (18/38) or combination therapy (32/42) (P <0.01 ivabradine versus carvedilol). Heart rate was reduced in all three groups, but to a greater extent by the combination. The distance walked on the 6-min walking test and the exercise time on MVO 2 test significantly improved in the ivabradine and combination groups (both P <0.01 versus baseline), as did peak VO 2 and VAT (P <0.01 for ivabradine and P <0.03 for combination versus carvedilol, respectively). No changes in these parameters were found with carvedilol. The patients receiving ivabradine or the combination had better quality of life (P <0.01 versus baseline for ivabradine and P <0.02 for combination), versus no change with carvedilol. Conclusion: Ivabradine alone or in combination with carvedilol is more effective than carvedilol alone at improving exercise tolerance and quality of life in HF patients.

Original languageEnglish
Pages (from-to)218-224
Number of pages7
JournalInternational Journal of Cardiology
Volume151
Issue number2
DOIs
Publication statusPublished - Sep 1 2011

Fingerprint

ivabradine
Heart Failure
Exercise
Quality of Life
Heart Rate
carvedilol
Exercise Tolerance

Keywords

  • Beta-blocker
  • Exercise capacity
  • Heart failure
  • Ivabradine
  • Quality of life
  • Rehabilitation

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

@article{205f74472dd741e3a25f7196654c083d,
title = "Effect of Carvedilol, Ivabradine or their combination on exercise capacity in patients with Heart Failure (the CARVIVA HF trial)",
abstract = "Aim: Patients with heart failure (HF) have reduced exercise capacity. The beneficial effect of beta-blocker on prognosis is not matched by an impact on exercise capacity and quality of life. We performed a randomised open blinded endpoint study to assess the effect of heart rate reduction with carvedilol, ivabradine, and their combination on exercise capacity in HF patients receiving maximal dose of ACE inhibitor. Methods and results: After a run-in phase patients were randomly allocated to 3 groups: carvedilol up to 25 mg bid (n = 38); ivabradine up to 7.5 mg bid (n = 41); and carvedilol/ivabradine up to 12.5/7.5 mg bid (n = 42). The maximal dose of study treatment was more frequently tolerated in patients receiving ivabradine (36/41) than in those receiving carvedilol (18/38) or combination therapy (32/42) (P <0.01 ivabradine versus carvedilol). Heart rate was reduced in all three groups, but to a greater extent by the combination. The distance walked on the 6-min walking test and the exercise time on MVO 2 test significantly improved in the ivabradine and combination groups (both P <0.01 versus baseline), as did peak VO 2 and VAT (P <0.01 for ivabradine and P <0.03 for combination versus carvedilol, respectively). No changes in these parameters were found with carvedilol. The patients receiving ivabradine or the combination had better quality of life (P <0.01 versus baseline for ivabradine and P <0.02 for combination), versus no change with carvedilol. Conclusion: Ivabradine alone or in combination with carvedilol is more effective than carvedilol alone at improving exercise tolerance and quality of life in HF patients.",
keywords = "Beta-blocker, Exercise capacity, Heart failure, Ivabradine, Quality of life, Rehabilitation",
author = "Maurizio Volterrani and Gennaro Cice and Giuseppe Caminiti and Cristiana Vitale and Salvatore D'Isa and {Perrone Filardi}, Pasquale and Flavio Acquistapace and Giuseppe Marazzi and Massimo Fini and Rosano, {Giuseppe M C}",
year = "2011",
month = "9",
day = "1",
doi = "10.1016/j.ijcard.2011.06.098",
language = "English",
volume = "151",
pages = "218--224",
journal = "International Journal of Cardiology",
issn = "0167-5273",
publisher = "Elsevier Ireland Ltd",
number = "2",

}

TY - JOUR

T1 - Effect of Carvedilol, Ivabradine or their combination on exercise capacity in patients with Heart Failure (the CARVIVA HF trial)

AU - Volterrani, Maurizio

AU - Cice, Gennaro

AU - Caminiti, Giuseppe

AU - Vitale, Cristiana

AU - D'Isa, Salvatore

AU - Perrone Filardi, Pasquale

AU - Acquistapace, Flavio

AU - Marazzi, Giuseppe

AU - Fini, Massimo

AU - Rosano, Giuseppe M C

PY - 2011/9/1

Y1 - 2011/9/1

N2 - Aim: Patients with heart failure (HF) have reduced exercise capacity. The beneficial effect of beta-blocker on prognosis is not matched by an impact on exercise capacity and quality of life. We performed a randomised open blinded endpoint study to assess the effect of heart rate reduction with carvedilol, ivabradine, and their combination on exercise capacity in HF patients receiving maximal dose of ACE inhibitor. Methods and results: After a run-in phase patients were randomly allocated to 3 groups: carvedilol up to 25 mg bid (n = 38); ivabradine up to 7.5 mg bid (n = 41); and carvedilol/ivabradine up to 12.5/7.5 mg bid (n = 42). The maximal dose of study treatment was more frequently tolerated in patients receiving ivabradine (36/41) than in those receiving carvedilol (18/38) or combination therapy (32/42) (P <0.01 ivabradine versus carvedilol). Heart rate was reduced in all three groups, but to a greater extent by the combination. The distance walked on the 6-min walking test and the exercise time on MVO 2 test significantly improved in the ivabradine and combination groups (both P <0.01 versus baseline), as did peak VO 2 and VAT (P <0.01 for ivabradine and P <0.03 for combination versus carvedilol, respectively). No changes in these parameters were found with carvedilol. The patients receiving ivabradine or the combination had better quality of life (P <0.01 versus baseline for ivabradine and P <0.02 for combination), versus no change with carvedilol. Conclusion: Ivabradine alone or in combination with carvedilol is more effective than carvedilol alone at improving exercise tolerance and quality of life in HF patients.

AB - Aim: Patients with heart failure (HF) have reduced exercise capacity. The beneficial effect of beta-blocker on prognosis is not matched by an impact on exercise capacity and quality of life. We performed a randomised open blinded endpoint study to assess the effect of heart rate reduction with carvedilol, ivabradine, and their combination on exercise capacity in HF patients receiving maximal dose of ACE inhibitor. Methods and results: After a run-in phase patients were randomly allocated to 3 groups: carvedilol up to 25 mg bid (n = 38); ivabradine up to 7.5 mg bid (n = 41); and carvedilol/ivabradine up to 12.5/7.5 mg bid (n = 42). The maximal dose of study treatment was more frequently tolerated in patients receiving ivabradine (36/41) than in those receiving carvedilol (18/38) or combination therapy (32/42) (P <0.01 ivabradine versus carvedilol). Heart rate was reduced in all three groups, but to a greater extent by the combination. The distance walked on the 6-min walking test and the exercise time on MVO 2 test significantly improved in the ivabradine and combination groups (both P <0.01 versus baseline), as did peak VO 2 and VAT (P <0.01 for ivabradine and P <0.03 for combination versus carvedilol, respectively). No changes in these parameters were found with carvedilol. The patients receiving ivabradine or the combination had better quality of life (P <0.01 versus baseline for ivabradine and P <0.02 for combination), versus no change with carvedilol. Conclusion: Ivabradine alone or in combination with carvedilol is more effective than carvedilol alone at improving exercise tolerance and quality of life in HF patients.

KW - Beta-blocker

KW - Exercise capacity

KW - Heart failure

KW - Ivabradine

KW - Quality of life

KW - Rehabilitation

UR - http://www.scopus.com/inward/record.url?scp=80052322413&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80052322413&partnerID=8YFLogxK

U2 - 10.1016/j.ijcard.2011.06.098

DO - 10.1016/j.ijcard.2011.06.098

M3 - Article

C2 - 21764469

AN - SCOPUS:80052322413

VL - 151

SP - 218

EP - 224

JO - International Journal of Cardiology

JF - International Journal of Cardiology

SN - 0167-5273

IS - 2

ER -